{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:43:26Z","timestamp":1789731806268,"version":"4.0.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"University Fund Limburg"},{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Axillary disease extent according to baseline [18F]fluorodeoxyglucose PET\/CT combined with pathological axillary treatment response has been proposed to guide de-escalation of axillary treatment for clinically node-positive breast cancer patients treated with neoadjuvant systemic therapy. The aim of this study was to assess whether axillary disease extent according to baseline [18F]fluorodeoxyglucose PET\/CT and breast cancer molecular subtype are predictors of axillary pCR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study included clinically node-positive patients treated with neoadjuvant systemic therapy in the prospective Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy (\u2018RISAS\u2019) trial (NCT02800317) with baseline [18F]fluorodeoxyglucose PET\/CT imaging available. The predictive value of axillary disease extent according to baseline [18F]fluorodeoxyglucose PET\/CT and breast cancer molecular subtype to estimate axillary pCR was evaluated using logistic regression analysis. Discriminative ability is expressed using ORs with 95% confidence intervals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 185 patients were included, with an axillary pCR rate of 29.7%. The axillary pCR rate for patients with limited versus advanced baseline axillary disease according to [18F]fluorodeoxyglucose PET\/CT was 31.9% versus 26.1% respectively. Axillary disease extent was not a significant predictor of axillary pCR (OR 0.75 (95% c.i. 0.38 to 1.46) (P = 0.404)). There were significant differences in axillary pCR rates between breast cancer molecular subtypes. The lowest probability (7%) was found for hormone receptor+\/human epidermal growth factor receptor 2\u2212 tumours. Using this category as a reference group, significantly increased ORs of 14.82 for hormone receptor+\/human epidermal growth factor receptor 2+ tumours, 40 for hormone receptor\u2212\/human epidermal growth factor receptor 2+ tumours, and 6.91 for triple-negative tumours were found (P &amp;lt; 0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Molecular subtype is a significant predictor of axillary pCR after neoadjuvant systemic therapy, whereas axillary disease extent according to baseline [18F]fluorodeoxyglucose PET\/CT is not.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjs\/znae203","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T13:45:44Z","timestamp":1726839944000},"source":"Crossref","is-referenced-by-count":6,"title":["Disease extent according to baseline [18F]fluorodeoxyglucose PET\/CT and molecular subtype: prediction of axillary treatment response after neoadjuvant systemic therapy for breast cancer"],"prefix":"10.1093","volume":"111","author":[{"given":"Florien J G","family":"van Amstel","sequence":"first","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+ , Maastricht ,","place":["The Netherlands"]},{"name":"Department of Surgery, Maastricht University Medical Center+ , Maastricht ,","place":["The Netherlands"]},{"name":"GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7905-6768","authenticated-orcid":false,"given":"Cornelis M","family":"de Mooij","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+ , Maastricht ,","place":["The Netherlands"]},{"name":"Department of Surgery, Maastricht University Medical Center+ , Maastricht ,","place":["The Netherlands"]},{"name":"GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine M","family":"Simons","sequence":"additional","affiliation":[{"name":"GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University , Maastricht ,","place":["The Netherlands"]},{"name":"Department of Radiotherapy, Erasmus Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mitea","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+ , Maastricht ,","place":["The Netherlands"]},{"name":"GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"van Diest","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty J","family":"Nelemans","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Maastricht University , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen C","family":"van der Pol","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Alrijne Hospital , Leiderdorp ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest J T","family":"Luiten","sequence":"additional","affiliation":[{"name":"Department of Surgery, Amphia Hospital Breda , Breda ,","place":["The Netherlands"]},{"name":"Tawam Breast Care Center, Tawam Hospital , Al Ain ,","place":["United Arab Emirates"]},{"name":"Department of Surgery, College of Medicine and Health Sciences, United Arab Emirates University , Al Ain ,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linetta B","family":"Koppert","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Erasmus Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein L","family":"Smidt","sequence":"additional","affiliation":[{"name":"Department of Surgery, Maastricht University Medical Center+ , Maastricht ,","place":["The Netherlands"]},{"name":"GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-3538","authenticated-orcid":false,"given":"Thiemo J A","family":"van Nijnatten","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+ , Maastricht ,","place":["The Netherlands"]},{"name":"GROW \u2013 Research Institute for Oncology and Reproduction, Maastricht University , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the REFINE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"de Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E G","family":"Boerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Boskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E M J","family":"Brouwers-Kuyper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M E","family":"Contant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A W F","family":"du M\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H J","family":"Heijmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ho-Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Hulsebosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A J","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B L R","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Kelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T M A L","family":"Klem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K P","family":"Koopmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M B I","family":"Lobbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M B E","family":"Menke-Pluijmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"de Monye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Sars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L H M","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"van Haaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"van Klaveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Veltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W J","family":"Vles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"2024093003472919400_znae203-B1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.breast.2021.07.015","article-title":"Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: an up-to-date meta-analysis of 3,578 patients","volume":"59","author":"Cao","year":"2021","journal-title":"Breast"},{"key":"2024093003472919400_znae203-B2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.clbc.2017.04.006","article-title":"A novel less-invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer by combining radioactive iodine seed localization in the axilla with the sentinel node procedure (RISAS): a Dutch prospective multicenter validation study","volume":"17","author":"van Nijnatten","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"2024093003472919400_znae203-B3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jso.26236","article-title":"Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments","volume":"123","author":"Esgueva","year":"2021","journal-title":"J Surg Oncol"},{"key":"2024093003472919400_znae203-B4","doi-asserted-by":"crossref","first-page":"1758835921996673","DOI":"10.1177\/1758835921996673","article-title":"Association between tumour molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery","volume":"13","author":"Hong","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"2024093003472919400_znae203-B5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/SLA.0000000000003126","article-title":"Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy","volume":"271","author":"Samiei","year":"2020","journal-title":"Ann Surg"},{"key":"2024093003472919400_znae203-B6","doi-asserted-by":"crossref","first-page":"e210891","DOI":"10.1001\/jamasurg.2021.0891","article-title":"Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease a systematic review and meta-analysis","volume":"156","author":"Samiei","year":"2021","journal-title":"JAMA Surg"},{"key":"2024093003472919400_znae203-B7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/jamasurg.2022.3907","article-title":"Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer","volume":"157","author":"Simons","year":"2022","journal-title":"JAMA Surg"},{"key":"2024093003472919400_znae203-B8","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/SLA.0000000000004356","article-title":"Diagnostic performance of noninvasive imaging for assessment of axillary response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis","volume":"273","author":"Samiei","year":"2021","journal-title":"Ann Surg"},{"key":"2024093003472919400_znae203-B9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4274\/ejbh.galenos.2021.2021-3-10","article-title":"Diagnostic value of axillary ultrasound, MRI, and 18F-FDG-PET\/CT in determining axillary lymph node status in breast cancer patients","volume":"18","author":"Akta\u015f","year":"2022","journal-title":"Eur J Breast Health"},{"key":"2024093003472919400_znae203-B10","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clbc.2021.07.011","article-title":"MINImal vs. MAXimal invasive axillary staging and treatment after neoadjuvant systemic therapy in node positive breast cancer: protocol of a Dutch multicenter registry study (MINIMAX)","volume":"22","author":"de Wild","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"2024093003472919400_znae203-B11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/bjs.10555","article-title":"Combined PET\u2013CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy","volume":"104","author":"Koolen","year":"2017","journal-title":"Br J Surg"},{"key":"2024093003472919400_znae203-B12","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1245\/s10434-018-6404-y","article-title":"Major reduction in axillary lymph node dissections after neoadjuvant systemic therapy for node-positive breast cancer by combining PET\/CT and the MARI procedure","volume":"25","author":"van der Noordaa","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"2024093003472919400_znae203-B13","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.ejca.2010.07.034","article-title":"Detection of extra-axillary lymph node involvement with FDG PET\/CT in patients with stage II\u2013III breast cancer","volume":"46","author":"Aukema","year":"2010","journal-title":"Eur J Cancer"},{"key":"2024093003472919400_znae203-B14","author":"NABON Breast Cancer Audit"},{"key":"2024093003472919400_znae203-B15","doi-asserted-by":"crossref","first-page":"e2213","DOI":"10.1097\/MD.0000000000002213","article-title":"Breast cancer subtype is associated with axillary lymph node metastasis: a retrospective cohort study","volume":"94","author":"He","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2024093003472919400_znae203-B16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/bjs.11963","article-title":"Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status","volume":"108","author":"Zetterlund","year":"2021","journal-title":"Br J Surg"},{"key":"2024093003472919400_znae203-B17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jss.2020.12.007","article-title":"Impact of breast cancer pretreatment nodal burden and disease subtype on axillary surgical management","volume":"261","author":"Ng","year":"2021","journal-title":"J Surg Res"},{"key":"2024093003472919400_znae203-B18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10549-022-06545-z","article-title":"Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol","volume":"193","author":"van Loevezijn","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2024093003472919400_znae203-B19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10549-020-05970-2","article-title":"Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?","volume":"185","author":"Garcia-Tejedor","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2024093003472919400_znae203-B20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","article-title":"The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB)","volume":"268","author":"Fayanju","year":"2018","journal-title":"Ann Surg"},{"key":"2024093003472919400_znae203-B21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/cancers13020171","article-title":"The prognostic value of lymph node involvement after neoadjuvant chemotherapy is different among breast cancer subtypes","volume":"13","author":"Laot","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024093003472919400_znae203-B22","year":"2023"},{"key":"2024093003472919400_znae203-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-018-3021-9","article-title":"Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial","volume":"19","author":"Henke","year":"2018","journal-title":"Trials"},{"key":"2024093003472919400_znae203-B24","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/bjs\/znac217","article-title":"Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey","volume":"109","author":"Gasparri","year":"2022","journal-title":"Br J Surg"},{"key":"2024093003472919400_znae203-B25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-012-2179-1","article-title":"Locoregional lymph node involvement on 18F-FDG PET\/CT in breast cancer patients scheduled for neoadjuvant chemotherapy","volume":"135","author":"Koolen","year":"2012","journal-title":"Breast Cancer Res Treat"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/111\/9\/znae203\/59328560\/znae203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/111\/9\/znae203\/59328560\/znae203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T03:47:46Z","timestamp":1727668066000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/doi\/10.1093\/bjs\/znae203\/7762547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,20]]},"published-print":{"date-parts":[[2024,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znae203","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,8,30]]},"article-number":"znae203"}}